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Abstract
Background An outcome measure to evaluate the neu-
rological function of patients with cervical myelopathy was
proposed by the Japanese Orthopaedic Association (JOA
score) and has been widely used in Japan. However, the
JOA score does not include patients’ satisfaction, disabil-
ity, handicaps, or general health, which can be affected by
cervical myelopathy. In 2007, a new outcome measure, the
Japanese Orthopaedic Association Cervical Myelopathy
Evaluation Questionnaire (JOACMEQ), which is a self-
administered questionnaire, was developed. However, the
influence of age and gender on the scores has not been fully
examined. The purpose of this study was to establish the
standard value of the JOACMEQ by age using healthy
volunteers.
Methods This study was conducted in 23 university
hospitals and their affiliated hospitals from September to
December 2011. The questionnaire included 24 questions
for evaluation of physical function of the cervical spine and
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spinal cord. A total of 1,629 healthy volunteers were
recruited for the study. The ages ranged from 20 to
89 years old.
Results The volunteers comprised 798 men and 831
women. In the elderly healthy volunteers, the JOACMEQ
scores decreased with age. In general, the scores for cer-
vical spine function and upper/lower extremity function
were retained up to the 60s, then decreased in the 70s and
80s. The scores for quality of life were retained up to the
70s; however, the score for bladder function was retained
up to the 40s, then declined with age from the 50s to 80s.
Conclusion The standard values of the JOACMEQ by
age were established. Differences in the scores were found
among different generations. Patients with cervical mye-
lopathy should be evaluated with this new self-adminis-
tered questionnaire taking into account the standard values
according to different ages.
Introduction
The members of the Subcommittee on the Evaluation of
Low Back Pain and Cervical Myelopathy, who belong to
the Clinical Outcomes Committee of the Japanese Ortho-
paedic Association, have composed a new self-adminis-
tered questionnaire, the Japanese Orthopaedic Association
Cervical Myelopathy Evaluation Questionnaire (JOA-
CMEQ), as a new outcome measure for patients with cer-
vical myelopathy [1] to solve problems associated with the
Japanese Orthopaedic Association score (JOA score),
which was established by the Japanese Orthopaedic
Association in 1975 [2] and was revised in 1994 [3]. The
JOACMEQ provides specific outcome measures including
patients’ disability, handicaps, and general health, which
are necessary to evaluate severity and treatment results in
patients with cervical myelopathy. It has been used in
many institutions nationwide. However, the influence of
age and gender on the scores has not been fully examined,
and there is a concern that the age-related decline in scores
may influence the evaluation. Therefore, standard values
according to age using the data of physically unimpaired
persons are needed to validate this new self-administered
questionnaire. The purpose of the current study was to
establish the standard values of the JOACMEQ according
to different ages using the results of healthy volunteers in
their 20s up to 80s.
Materials and methods
This study was conducted in 23 university hospitals and
their affiliated hospitals from September to December in
2011. A total of 1,644 healthy volunteers were recruited for
the study. They were self-supporting and required no
medical assistance for orthopedic diseases. Subjects with
cognitive impairment who could not understand the ques-
tionnaires and those who were under treatment for ortho-
pedic disorders and/or had a history of operation for spinal
disorders including the cervical spine were excluded from
the study. Medical professionals were also excluded from
the subjects. The healthy volunteers were grouped by
gender and decade from 20 to 80 years of age. Five healthy
individuals within each age group and from both genders
were surveyed at each institution. This study was reviewed
and approved by the institutional review board of each
institution, and all subjects provided informed consent
prior to the inclusion to the study.
The questionnaire included 24 questions in five
domains, cervical spine function, upper extremity function,
lower extremity function, bladder function, and quality of
life. Visual analog (VAS) scales were used to evaluate the
degree of pain or stiffness in the neck or shoulders, tight-
ness in the chest, pain or numbness in the arms or hands,
and pain or numbness from the chest to toes (Table 1). A
respondent recalled his or her physical condition during the
previous 1 week and circled the number of an answer for
each question that best fit his or her condition. If a
respondent’s condition changed depending on the day or
the time, he or she circled the number representing ‘‘the
worst condition.’’ The JOACMEQ score was calculated as:
cervical spine function: Q1-1 9 20 ? Q1-2 9 10 ? Q1-
3 9 15 ? Q1-4 9 5 - 50; upper extremity function:
(Q1-4 9 5 ? Q2-1 9 10 ? Q2-2 9 15 ? Q2-3 9 5 ?
Q3-1 9 5 - 40) 9 100 7 95; lower extremity function: Q3-
1 9 10 ? Q3-2 9 10 ? Q3-3 9 15 ? Q3-4 9 5 ? Q3-5 9
5 - 45) 9 100 7 110; bladder function: (Q4-1 9 10 ?
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Table 1 The JOA Cervical Myelopathy Evaluation Questionnaire (JOACMEQ)
With regard to your health condition during the last week, please circle the one item 
number of the answer for the following questions that best applies. If your condition 
varies depending on the day or the time, circle the item number of your condition at its 
worst.
Q1-1 While in the sitting position, can you look up at the ceiling by tilting your 
head upward?
1) Impossible 2) Possible to some degree (with some efforts)
3) Possible without difficulty
Q1-2 Can you drink a glass of water without stopping despite the neck 
symptoms?
1) Impossible 2) Possible to some degree
3) Possible without difficulty
Q1-3 While in the sitting position, can you turn your head toward the person 
who is seated to the side but behind you and speak to that person while looking at 
his/her face?
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Table 1 continued
1) Impossible 2) Possible to some degree
3) Possible without difficulty
Q1-4 Can you look at your feet when you go down the stairs?
1) Impossible 2) Possible to some degree
3) Possible without difficulty
Q2-1 Can you fasten the front buttons of your blouse or shirt with both hands?
1) Impossible 2) Possible if I spend time.
3) Possible without difficulty
Q2-2 Can you eat a meal with your dominant hand using a spoon or a fork?
1) Impossible 2) Possible if I spend time.
3) Possible without difficulty
Q2-3 Can you raise your arm? (Answer for the weaker side.)
1) Impossible
2) Possible up to shoulder level
3) Possible though the elbow and/or wrist is a little flexed
4) I can raise it straight upward
Q3-1 Can you walk on a flat surface?
1) Impossible
36 N. Tanaka et al.
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Table 1 continued
2) Possible but slowly even with support
3) Possible only with the support of a handrail, a cane, or a walker
4) Possible but slowly without any support
5) Possible without difficulty
Q3-2 Can you stand on either leg without the support of your hand? (the need to 
support yourself)
1) Impossible with either leg
2) Possible on either leg for more than ten seconds
3) Possible on both legs individually for more than ten seconds
Q3-3 Do you have difficulty in going up the stairs?
1) I have great difficulty. 2) I have some difficulty.
3) I have no difficulty.
Q3-4 Do you have difficulty in one of the following motions; bending forward, 
kneeling or stooping?
1) I have great difficulty. 2) I have some difficulty.
3) I have no difficulty.
Q3-5 Do you have difficulty in walking more than 15 minutes?
1) I have great difficulty. 2) I have some difficulty.
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Table 1 continued
3) I have no difficulty.
Q4-1 Do you have urinary incontinence?
1) Always
2) Frequently
3) When retaining urine over a period of more than 2 hours
4) When sneezing or straining
5) No
Q4-2 How often do you go to the bathroom at night?
1) Three times or more 2) Once or twice 3) Rarely
Q4-3 Do you have a feeling of residual urine in your bladder after voiding?
1) Most of the time 2) Sometimes 3) Rarely
Q4-4 Can you initiate (start) your urine stream immediately when you want to 
void?
1) Usually not 2) Sometimes 3) Most of the time
Q5-1 How is your present health condition?
1) Poor 2) Fair 3) Good 4) Very good 5) Excellent
Q5-2 Have you been unable to do your work or ordinary activities as well as you 
would like?
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Table 1 continued
1) I have not been able to do them at all.
2) I have been unable to do them most of the time.
3) I have sometimes been unable to do them.
4) I have been able to do them most of the time.
5) I have always been able to do them.
Q5-3 Has your work routine been hindered because of the pain?
1) Greatly 2) Moderately 3) Slightly (somewhat)
4) Little (minimally) 5) Not at all
Q5-4 Have you been discouraged and depressed?
1) Always 2) Frequently 3) Sometimes 4) Rarely 5) Never
Q5-5 Do you feel exhausted?
1) Always 2) Frequently 3) Sometimes 4) Rarely 5) Never
Q5-6 Have you felt happy?
1) Never 2) Rarely 3) Sometimes 4) Almost always 5) Always
Q5-7 Do you think you are in decent health?
1) Not at all (my health is very poor)
2) Barely (my health is poor)
3) Not very much (my health is average health)
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Table 1 continued
4) Fairly (my health is better than average)
5) Yes (I am healthy)
Q5-8 Do you feel your health will get worse?
1) Very much so 2) A little bit at a time
3) Sometimes yes and sometimes no 4) Not very much 5) Not at all
Regarding 0 as “no pain (numbness) at all” and 10 as “the most intense pain (numbness) 
imaginable,” mark a point between 0 and 10 on the lines below to show the degree of 
your pain (numbness) when your symptom was at its worst during the last week.
If you feel pain or stiffness in your neck or shoulders, mark the degree
0 10
If you feel tightness in your chest, mark the degree
0 10
If you feel pain or numbness in your arms or hands, mark the degree (If there is pain in 
both limbs, then the worse of the two)
40 N. Tanaka et al.
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Q4-2 9 5 ? Q4-3 9 10 ? Q4-4 9 5 - 30) 9 100 7 80;
quality of life: (Q5-1 9 3 ? Q5-2 9 2 ? Q5-3 9 2 ?
Q5-4 9 5 ? Q5-5 9 4 ? Q5-6 9 3 ? Q5-7 9 2 ? Q5-8 9
3 - 24) 9 100 7 96. The score of each domain ranges
from 0 to 100 points, which is proportional to the patients’
clinical conditions [4–6].
The data of those over 90 years old were extracted from
the study; then the answers of 1,629 volunteers were used
for the analysis. Irrelevant data where subjects did not
respond to all the questions or clearly inappropriate
answers in which subjects did not follow instructions were
excluded from the analyses for each domain. The Steel–
Dwass test was used for multiple comparisons among
different generations, and the Jonckheere-Terpstra test was
used to determine age trends in each gender by domain.
P \ 0.05 was considered significant.
Results
The volunteers comprised 798 men and 831 women. The
gender and age distributions of the volunteers are shown in
Table 2. The distribution of the scores for each domain in
the JOACMEQ (from 10th to 90th percentile) are shown in
Tables 3, 4, 5, 6, and 7. In the elderly healthy volunteers,
the JOACMEQ scores decreased with age. The average
score for cervical spine function was more than 90 points in
the younger generation from the 20s to 60s, and in those in
their 70s and 80s, the average score decreased to 80 points
and 70 points, respectively (Table 3). There were signifi-
cant differences in the average scores between the younger
generation in their 20s to 60s and the elderly generation in
their 80s in both genders. The average score for upper
extremity function was more than 95 points in those in their
20s to 70s and decreased to 80 points for those in their 80s
in both genders (Table 4). There were also significant
differences in the average scores between the younger
generations and elderly in their 80s in both genders. The
average lower extremity function score was more than 95
points in those in their 20s to 60s in males and decreased to
70 points in their 80s. In females, the average score was
more than 95 points in those in their 20s to 40s and
decreased to \95 points in their 50s and 60s; in 70s and
80s, the average score further decreased to 80 points and 60
points, respectively (Table 5). There were significant dif-
ferences in the average scores between the younger gen-
eration below 70 years of age and elderly generation above
70 in both genders. The average bladder function score was
more than 90 points in the young generations in their 20s to
Table 1 continued
0 10
If you feel pain or numbness from chest to toe, mark the degree
0 10
0：No pain (numbness) at all
10：The worst state imaginable
Table 2 Gender and age distribution of volunteers
Age groups (years) Male Female Total
20–29 115 120 235
30–39 122 117 239
40–49 117 120 237
50–59 113 123 236
60–69 118 122 240
70–79 109 117 226
80–89 104 112 216
Total 798 831 1,629
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50s in both genders; the average score decreased to 80
points in those in their 60s and 70s and to 70 points in their
80s in both genders (Table 6). There were significant dif-
ferences in the average scores between the younger gen-
erations in their 20s to 40s and elderly generations in their
50s to 80s in both genders. The average quality of life score
of each generation was approximately 70 points in the
generations in their 20s to 60s in both genders and
decreased to the 60–70 points in their 70s in males and at
70s and 80s in females (Table 7). There were significant
differences in the average scores between the younger
generations and elderly generation in their 80s in both
genders. With regard to the age trend on the Jonckheere–
Terpstra test, scores tended to decrease in the five domains
as age increased in both genders.
The scores for each domain in the VAS for pain or
stiffness in the neck or shoulders, tightness in the chest,
pain or numbness in the arms or hands, and pain or
numbness from the chest to toe are shown in Tables 8, 9,
10, and 11. The volunteers recorded the VAS scores as a
mark on the bar scale as a value according to the
instructions in the attached document. However, if both a
mark on the bar scale and a numerical value on the sheet
were present, the former was used for the analysis. The
VAS scores for all domains increased with age; however,
the score for pain or stiffness in the neck or shoulders in
females tended to decrease with age (Table 8). The scores
of the generation in their 40s and 50s for females were
significantly higher than those of the elderly in their 70s
and 80s. Tightness in the chest was not a frequent com-
plaint in either gender (Table 9), and there were no sig-
nificant differences in the scores among different
generations in either gender. The VAS score for pain or
numbness in the arms or hands was more frequent in
males in those who were in their 60s and above and in
their 50s and above in females, and it was a common
complaint in the 80s in both genders (Table 10). There
were significant differences in the scores between the
younger generation and elderly in their 80s in both gen-
ders. Also, the score for pain or numbness from the chest
to toe was more frequent in those over 60 years in males
and over 50 years in females, with a particularly high
incidence in those in their 80s in both genders (Table 11).
In male volunteers, there were significant differences in
the scores between the younger generations in their 20s to
50s and elderly generations in their 60s to 80s, and in
females, there were significant differences in the scores
between the younger generations in their 20s to 60s and
elderly in their 70s and 80s. Regarding age trends among
the VAS scores, the scores tended to increase with age in
both genders across all domains, except neck stiffness in
women, which showed a tendency to decrease with an
increase in age.T
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Discussion
Spinal cord function related to cervical myelopathy was
assessed by the JOA (Japanese Orthopaedic Association)
score, which was established in 1975 [2] and revised in
1994 [3]. The original JOA score was used as a functional
assessment for cervical myelopathy worldwide, and the
high inter- and intraobserver reliability of the score was
demonstrated [7]. Although the JOA score attaches
importance to the physical function of the upper and lower
extremities and bladder dysfunction, the score does not
include cervical spine function, including neck pain, a stiff
neck, patient satisfaction, disability, or QOL.
The JOACMEQ was developed as a new self-adminis-
tered questionnaire to measure outcomes in patients with
cervical myelopathy [1] to solve problems of the original
JOA score. With this new score, specific outcome measures
of patient satisfaction, disability, handicaps, and general
health, which are necessary information to evaluate
patients with cervical myelopathy, are obtained. However,
the influence of age and gender on the score has not been
examined, and concern exists that the age-related decline
may influence the evaluation.
In the current study, 1,629 healthy volunteers were
recruited in 23 institutions to establish the standard values
of the JOACMEQ by age using data obtained from healthy
volunteers in their 20s to 80s.
In the elderly healthy volunteers, the JOACMEQ scores
decreased with age. As for upper and lower extremity
function, there was a relatively weak influence of age and
gender; however, there was a strong influence of aging on
bladder function. The bladder function scores were retained
only up to 40 years of age, then declined significantly after
50 years. Also in the QOL score, even in the younger vol-
unteers, the average score did not reach the full score of 100.
The authors believe that the standard scores for cervical
spine function, upper extremity function, and lower
extremity function should be regarded as 95 points for
relatively young patients under the age of 60, and for
bladder function, the lower limits of the score for healthy
subjects should be regarded as 80 points. The QOL scores
may not be altered with age or gender, and the standard
value should be regarded as over 70 points. There was a
significant decrease in the JOACMEQ score in those in
their 80s in the current study. These results indicate that
persons older than 80 years of age might have accompa-
nying age-related degeneration of the central and/or
peripheral nervous systems, impairment of motor func-
tions, and other general complications even if they look
healthy.
As for the VAS, an influence of age was also found in
the healthy volunteers. Most domains in the VAS were
influenced by age-related degenerative diseases of the
cervical spine. In the domain of pain or numbness in the
arms or hands, the scores in the elderly generation were
significantly higher than those in the younger generations.
These results may be induced by peripheral arterial dis-
eases or neuropathy that may exist in the elderly popula-
tion. The VAS in most domains tended to increase with
age; however, in females, the VAS for pain or stiffness in
the neck or shoulders decreased with age. These findings
suggest that pain or stiffness in the neck or shoulders may
not be affected by age-related degenerative conditions of
the cervical spine, but may be caused by muscular or
posture distress related to office work or household work in
relatively younger female generations.
The JOACMEQ was designed as a self-administered
questionnaire to evaluate spinal functions in myelopathy
patients and may be suitable for a relative evaluation in
each case and may not be suitable for direct comparison
with other patients. We can judge that a treatment is
‘‘effective’’ for a patient if: (1) the patient answers all
questions necessary to calculate the score of a domain and
an increase of C20 points is obtained for that score, or (2)
the functional score after treatment is [90 points even if
the answers for the unanswered questions were supposed to
be the worst possible choice. The effectiveness of the
treatment can be evaluated based only on the two above-
mentioned conditions [8]. Although these criteria were
chosen based on the extensive analysis of a considerable
amount of data, which was obtained in a series of previous
studies, by the statistics expert, a revision may be necessary
for the elderly populations. According to our results, the
average functional scores of most domains in normal
healthy volunteers were \90 points in the elderly popula-
tion in the 70s and 80s. In the JOACMEQ, exceptional
attention to judgment about the treatment or relative
evaluation in the assessment for elderly individuals over
70 years old might be needed.
As for limitations of this study, the detailed medical
history and general health of the volunteers were not fully
assessed; therefore, potentially unhealthy subjects might
have been included in the study group, especially in the
elderly generations. Also, the mental status was not
investigated to exclude psychiatric diseases. These physical
and mental conditions may have affected the score.
In conclusion, the standard values for the five domains
of the JOACMEQ were established using healthy volun-
teers. Physicians should be aware that there are differences
in the scores among different generations. Patients with
cervical myelopathy should be evaluated with this new
self-administered questionnaire, JOACMEQ, taking the
standard value in each generation into account. This new
self-administered questionnaire can be used to evaluate the
outcomes in patients with cervical myelopathy more effi-
ciently and will be helpful to identify the most appropriate
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surgical and medical treatments, thereby improving medi-
cal skills.
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